Phase I study of ON 01910.Na, a novel modulator of the polo-like kinase 1 pathway, in adult patients with solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Cell Cycle Proteins
  • Gene Expression Regulation, Neoplastic
  • Glycine
  • Protein-Serine-Threonine Kinases
  • Proto-Oncogene Proteins
  • Sulfones

abstract

  • ON 01910.Na showed a distinct but moderate toxicity pattern. The recommended phase II dose of ON 01910.Na with this schedule of administration is 3,120 mg. Single-agent activity was documented in an ovarian cancer patient.

publication date

  • December 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4824307

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.17.9788

PubMed ID

  • 18955447

Additional Document Info

start page

  • 5504

end page

  • 10

volume

  • 26

number

  • 34